We only focus on off-the-shelf, allogeneic NKT cell therapies
OUR PIPELINE
encompasses four products. Our lead product (TINK-101) is an off-the-shelf, non-genome edited CD7 CAR-iNKT cell therapy with the potential to treat T-cell leukemia, lymphoma, and AML. Another product, TINK-104, an unmodified native type III NKT cell therapy, also targets AML. We are now exploring the potential of CAR-iNKT in autoimmune diseases (TINK-102) and solid tumors (TINK-103).